Last reviewed · How we verify
Prednisolone Acetate 1% Oph Susp
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators.
Prednisolone acetate is a corticosteroid that suppresses inflammatory and immune responses in the eye by inhibiting phospholipase A2 and reducing production of inflammatory mediators. Used for Inflammatory conditions of the anterior segment of the eye (conjunctivitis, keratitis, iritis, iridocyclitis), Post-operative inflammation following ocular surgery, Allergic conjunctivitis.
At a glance
| Generic name | Prednisolone Acetate 1% Oph Susp |
|---|---|
| Also known as | PRED FORTE®, OMNIPRED®, Prednisolone Acetate, Omnipred, Pred Forte |
| Sponsor | SR Cornea Consultants |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
As a glucocorticoid, prednisolone acetate binds to cytoplasmic glucocorticoid receptors, translocates to the nucleus, and modulates gene expression to decrease synthesis of prostaglandins, leukotrienes, and cytokines. This reduces inflammation, edema, and immune cell infiltration in ocular tissues. The acetate ester formulation enhances corneal penetration when applied topically as an ophthalmic suspension.
Approved indications
- Inflammatory conditions of the anterior segment of the eye (conjunctivitis, keratitis, iritis, iridocyclitis)
- Post-operative inflammation following ocular surgery
- Allergic conjunctivitis
Common side effects
- Elevated intraocular pressure
- Posterior subcapsular cataract formation
- Secondary ocular infection
- Ocular irritation or discomfort
Key clinical trials
- Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (PHASE4)
- Effect of Intraoperative Dexamethasone on Post-op Dry Eye (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery (PHASE4)
- DEXTENZA Compared to Topical Steroid Therapy Prior to Cataract Surgery in Patients Who Receive Premium Intraocular Lenses (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolone Acetate 1% Oph Susp CI brief — competitive landscape report
- Prednisolone Acetate 1% Oph Susp updates RSS · CI watch RSS
- SR Cornea Consultants portfolio CI